Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare ...

Analysts previously noted that the HARBOR study’s success would be a key justifier of the Avidity acquisition’s price tag.

Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular ...

Novartis' $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company's lead assets, delpacibart braxlosiran (del-brax), has posted a mid-stage win in the ...

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s ...

By Bhanvi Satija LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for its muscle ...

Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board's oversight of ...